Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
04 Décembre 2023 - 2:00PM
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics”
or “Elicio”), a clinical-stage biotechnology company developing a
pipeline of novel immunotherapies for the treatment of cancer,
today announced that Robert Connelly, Chief Executive Officer,
will present at the upcoming H.C. Wainwright 4th Annual Precision
Oncology Virtual Conference on December 6, 2023 at 10:30 AM ET.
A live webcast of the presentation will be accessible under
“Events” in the Investors section of Elicio’s website and will be
available on-demand for 90 days following the event.
About Elicio TherapeuticsElicio Therapeutics is
a clinical-stage biotechnology company developing a pipeline of
novel immunotherapies for the treatment of cancer. By combining
expertise in immunology and immunotherapy, Elicio is engineering
investigational Amphiphile (AMP) immunotherapies intended to
precisely target and fully engage the lymph nodes, the site in our
bodies where the immune response is orchestrated. Elicio is
engineering lymph node-targeted AMPlifiers, immunomodulators,
adjuvants and vaccines for an array of aggressive cancers.
Media ContactKristin PolitiLifeSci
Communicationskpoliti@lifescicomms.com973-495-5221
Investor Relations ContactHeather
DiVecchiaElicio TherapeuticsIR@elicio.com857-209-0153
Elicio Therapeutics (NASDAQ:ELTX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Elicio Therapeutics (NASDAQ:ELTX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024